Welcome to our dedicated page for Regenerative Medical Technology Group SEC filings (Ticker: RMTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regenerative Medical Technologies Group, Inc. (RMTG) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. RMTG is an SEC-reporting regenerative medicine company with file number 000-56010, and its filings offer detail on operations conducted through its Global Stem Cells Group subsidiary, including product sales, equipment sales, patient procedures, and physician training activities.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand how RMTG’s four main revenue channels and turnkey membership model contribute to overall performance. These reports typically describe the company’s integrated business model, which links clinical operations, product and equipment distribution, manufacturing through its CELLGENIC brand, and education and certification programs delivered via the International Society for Stem Cell Application (ISSCA).
The filings page may also include current reports on Form 8-K that disclose material events, such as new affiliate agreements, manufacturing milestones, or significant business developments, as well as proxy statements that discuss corporate governance and matters submitted to shareholders. For monitoring reporting timeliness, documents such as the company’s Form NT 10-Q notification of late filing provide context on delays in periodic reports and the expected timing of submissions.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify information related to revenue sources, operating structure, and risk factors. Real-time updates from EDGAR allow users to see new filings as they are posted, while access to ownership and insider-related forms, when available, can help track management’s alignment with shareholders.
By using the RMTG SEC filings page, investors can examine the company’s official financial statements, disclosures about its regenerative medicine operations, and narrative explanations that support a more informed view of its business.
Regenerative Medical Technology Group Inc. (RMTG) reports higher revenue but deepening losses for the nine months ended September 30, 2025. Revenue rose to $3,528,393 from $2,596,671, driven entirely by Global Stem Cells Group, with growth in training, product supplies, and patient procedures. Cost of revenue increased, but the company still generated gross profit of $2,031,283.
Operating expenses climbed to $2,592,171, and heavy interest and financing costs pushed total other expense to $5,858,678, resulting in a net loss of $6,419,566 versus $4,924,785 a year earlier. The balance sheet shows assets of $4,519,827 against total liabilities of $34,574,268 and a stockholders’ deficit of $30,054,441. The company discloses a working capital deficit of $15,762,714 and an accumulated deficit of $73,972,668 and states there is substantial doubt about its ability to continue as a going concern.
Regenerative Medical Technology Group Inc. (RMTG) filed a Form 12b-25 (NT 10-Q) for its Quarterly Report for the period ended September 30, 2025.
The company says it could not, without unreasonable effort or expense, complete the financial statements and related disclosures. It expects to file the Form 10-Q within the five-day grace period provided by Rule 12b-25.